Abstract

Identification of new vaccine adjuvants with immunopotentiating properties commonly involves in vitro evaluations of candidate compounds for their ability to stimulate cells of the immune system. Subsequent elaborate experiments are then performed on only the positive candidates. Here we show how this strategy may miss good candidates due to context-dependent supramolecular characteristics of the candidate compounds, since both a specific molecular structure and the correct presentation of specific parts of the compounds are required for successful stimulation of the cells. Nevertheless, the supramolecular structure is rarely evaluated although changes in this structure may have a drastic impact on the presentation of the compounds to the cells. Synthetic analogues of the mycobacterial cell wall lipid monomycoloyl glycerol (MMG) possess immunopotentiating properties, but their biophysical characteristics are largely unresolved and the structural features determining their immunoactivating properties have been poorly explored. In the present study, we demonstrate that the immunostimulatory activity in vitro correlates with the supramolecular characteristics of the self-assembled MMG nanostructures. Thus, a series of MMG analogues displaying different stereochemistry in the hydrophobic moiety and the polar headgroup were designed and synthesized with different alkyl chain lengths. Stimulation of human monocyte-derived dendritic cells in vitro was clearly dependent on the stereochemistry of the hydrophobic part and on the alkyl chain length but not on the stereochemistry of the hydrophilic glycerol moiety. Small-angle X-ray scattering (SAXS) analysis showed that the immunoactivating analogues self-assembled into lamellar phases whereas the biologically inert analogues adopted inverse hexagonal phases. Langmuir monolayers confirmed that analogues with opposite lipid acid configurations displayed different packing modes. These data demonstrate that the biophysical properties and the lipid molecular structure are major determinants for the ability of the MMG analogues to activate antigen-presenting cells. Our findings emphasize the importance of investigating the biophysical and structural properties when assessing the effect of adjuvants in vitro.

Highlights

  • Vaccination has been successfully used as an effective means of preventing infectious diseases and reducing disease burden, but efficient vaccines are still not available for certain infectious diseases such as AIDS, malaria and tuberculosis (TB)

  • The diastereomers could be distinguished by NMR due to minor differences in the chemical shi s of the signals corresponding to the atoms of the polar glycerol headgroups and of the adjacent part of the hydrophobic lipid acid moiety.[5]

  • The proin ammatory cytokine panel measured was extended to include interleukin 6 (IL-6) and interleukin 8 (IL-8), and we consistently found that human dendritic cells (DCs) activation was highly dependent on the lipid chain length: for the investigated concentration range, the monomycoloyl glycerol (MMG) analogues with longer alkyl chains, i.e. C14/C15 (MMG-1) and C16/C17 (MMG-2), were able to signi cantly activate the cells, as evident by an enhanced production of all the investigated proin ammatory cytokines, as compared to the MMG analogues with shorter lipid chains (MMG-3 and MMG-4), which were less capable of stimulating the cells (Fig. 3)

Read more

Summary

Introduction

Vaccination has been successfully used as an effective means of preventing infectious diseases and reducing disease burden, but efficient vaccines are still not available for certain infectious diseases such as AIDS, malaria and tuberculosis (TB). A promising strategy is the subunit vaccine technology, which is based on well-de ned and highly puri ed antigenic components of the pathogen combined with immunopotentiating compounds that enhance and control the nature of the immune response. These immunopotentiating compounds, termed adjuvants, o en resemble pathogen-associated molecular patterns (PAMPs) and they can activate the immune system by interacting with pattern-recognition receptors (PRRs) on antigen-presenting cells (APCs). Adjuvants are o en initially evaluated and characterized by their ability to stimulate APCs in vitro. Examples of adjuvants are monophosphoryl lipid A (MPL), which has been shown to stimulate the cells through binding to Toll-like receptor 41 and trehalose dibehenate (TDB) and trehalose dimycolate (TDM), which signal through the C-type lectin receptor (CLR) Mincle.[2,3] Paper

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.